ProQR Therapeutics

Update in progress

PRQR (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing novel medicines using its Axiomer RNA editing platform for genetic disorders. Its pipeline includes AX-0810 for NTCP-related cholestatic diseases, AX-2402 for Rett syndrome, AX-2911 for metabolic dysfunction-associated steatohepatitis, and AX-1412 for cardiovascular diseases. It collaborates with Eli Lilly on liver and nervous-system targets and was founded in 2012, based in Leiden, the Netherlands.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive